Anti-CD19 chimeric antigen receptor T cell therapy (Immune cell)

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameAnti-CD19 chimeric antigen receptor T cell therapy (Immune cell)
Drug Alias NameICAR19 CAR-T cells (Immune Cell)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-CellLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesImmune Cell Inc
China Registration ClassN/A

Develop Information

Active CompaniesImmune Cell Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLeukemia, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A